6-K - Burning Rock Biotech Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Burning Rock Biotech Limited reported unaudited financial results for Q4 and full year 2025, with full-year revenue increasing 4.6% to RMB539.6 million and net loss narrowing significantly to RMB55.3 million from RMB346.6 million in 2024. The company highlighted the granting of a core U.S. patent for its ELSA-seq technology and regulatory progress for its OncoScreen BCMatch Tissue Kit.

Key Takeaways

1Full year 2025 revenue was RMB539.6 million (US$77.2 million), a 4.6% increase from RMB515.8 million in 2024.

2Net loss for 2025 narrowed to RMB55.3 million (US$7.9 million), compared to a net loss of RMB346.6 million in 2024.

3Q4 2025 revenue remained relatively stable at RMB126.3 million (US$18.1 million) compared to RMB126.0 million in the same period of 2024.

4Pharma research and development services revenue grew 34.5% year-over-year to RMB155.5 million (US$22.2 million) for the full year 2025.

5Operating expenses decreased 36.4% year-over-year to RMB457.8 million (US$65.5 million) for the full year 2025.

6The core patent for ELSA-seq technology (Patent No.: US 12460202 B2) was granted by the USPTO.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Fourth Quarter and Full Year 2025

Metric	Value	Basis	Prior Period
Revenue	$126.30		$126.00
Revenue	$18.10
Gross Profit	$98.60	GAAP	$89.40
Gross Margin	78%	GAAP	71%
Net Loss	$15.40	GAAP	$81.30
Revenue	$539.60		$515.80
Revenue	$77.20
Gross Profit	$402.90	GAAP	$362.40
Gross Margin	74.7%	GAAP	70.3%
Net Loss	$55.30	GAAP	$346.60

Exhibits (2)

6-K

FORM 6-K

99.1

EX-99.1